Astellas Pharma

Astellas Pharma PEG

The PEG Ratio (Price/Earnings-to-Growth) of Astellas Pharma (4503.T) as of Nov 7, 2026 is 0.35. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 2.00 — a change of -82.59% (lower).

PEG

0.35

YoY

-82.59%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Astellas Pharma is 2026 0.35 . PEG Ratio (Price/Earnings-to-Growth) of Astellas Pharma was 2025 2.00 . It decreases by -82.59% lower compared to the previous year.

The Astellas Pharma PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PEG
Date
PEG
Jan 1, 2019
0.46 JPY
Jan 1, 2020
0.52 JPY
Jan 1, 2021
0.84 JPY
Jan 1, 2022
0.82 JPY
Jan 1, 2023
1.03 JPY
Jan 1, 2024
5.95 JPY
Jan 1, 2025
2.00 JPY
Jan 1, 2026
0.35 JPY
The Astellas Pharma PEG history
YEARPEGYoY
0.35-82.59%
2.00-66.41%
5.95+479.14%
1.03+25.70%
0.82-2.82%
0.84+62.05%
0.52+13.74%
0.46-25.91%
0.62+32.80%
0.46-11.44%
0.52-29.86%
0.75-33.11%
1.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Astellas Pharma Stock analysis

What does Astellas Pharma do? Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Astellas Pharma stock

PEG Ratio (Price/Earnings-to-Growth) of Astellas Pharma is 0.35 in 2026.

PEG Ratio (Price/Earnings-to-Growth) of Astellas Pharma changed from 2.00 to 0.35, representing a -82.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Astellas Pharma since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Astellas Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Astellas Pharma

All Key Metrics — Astellas Pharma